multiple myeloma treatment

New data on ZOLINZA in combination with Bortezomib

harminka — Tue, 09 Dec 2008 14:46:26 -0600

ZOLINZA® (vorinostat) in Combination with Bortezomib Showed Clinical Response in Early Investigational Studies of Patients with Relapsed or Refractory Multiple Myeloma

Drug combination stabilizes disease for relapsed multiple myeloma patients

harminka — Tue, 09 Dec 2008 14:37:02 -0600

Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment.

Exploing issues related to multiple myeloma treatment

harminka — Tue, 07 Oct 2008 01:06:08 -0500

Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients.

New therapeutic options for newly diagnosed multiple myeloma patients

harminka — Mon, 10 Dec 2007 14:05:34 -0600

Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy.

In investigational studies of patients with advanced multiple myeloma

harminka — Mon, 10 Dec 2007 03:41:14 -0600

Results from two investigational Phase I trials of ZOLINZA® (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma. Data from one study showed that 10 of 21 (48 percent) evaluable patients had a partial or minimal response from the ZOLINZA and bortezomib combination treatment.

Multiple myeloma clinical trial shows survival benefit with lower dose of steroids

harminka — Mon, 10 Dec 2007 03:31:24 -0600

Results of Eastern Cooperative Oncology Group Phase III clinical trial E4A03, for multiple myeloma, showing significantly better overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone, were reported today by S. Vincent Rajkumar, M.D. at the American Society of Hematology’s annual meeting.

Drug combination effective against multiple myeloma

harminka — Fri, 23 Nov 2007 11:59:27 -0600

Pairing a new thalidomide derivative with a steroid slows progress of multiple myeloma, an incurable bone marrow cancer, and prolongs the lives of patients who have relapsed from previous treatment, researchers report in the Nov. 22 New England Journal of Medicine.

Oral drug sets new survival standard for bone marrow cancer

harminka — Fri, 23 Nov 2007 11:24:19 -0600

Researchers from the Abramson Cancer Center of the University of Pennsylvania announced today that findings from two large, international clinical trials show unprecedented survival for patients with multiple myeloma, a cancer that occurs in the blood-making cells of bone marrow.

Gene profiling To single out multiple myeloma, guide therapy

harminka — Tue, 18 Sep 2007 10:09:11 -0500

Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potentially guide therapy in the future.

Researchers identify signaling protein for multiple myeloma

harminka — Mon, 10 Sep 2007 13:09:15 -0500

Researchers at Emory University’s Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival. Their research may result in identification of a new therapeutic target for treating multiple myeloma.

Genetic abnormalities lead to NF-κB activation in multiple myeloma

harminka — Mon, 13 Aug 2007 12:11:32 -0500

Two new studies may lead to the development of more effective therapies for individuals with multiple myeloma (MM), a common and incurable blood cell cancer.

Changing way physicians treat multiple myeloma

harminka — Tue, 05 Jun 2007 04:13:00 -0500

Moffitt clinical director part of National Myeloma Forum recommending additional studies that further evaluate new front-line oral Revlimid treatment combinations as an alternative to stem cell transplant in newly diagnosed patients